Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1137-1145. doi: 10.1051/medsci/2019214. Epub 2020 Jan 6.

[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology].

[Article in French; Abstract available in French from the publisher]

Author information

Centre Paul Strauss, Institut de Cancérologie de Strasbourg, Strasbourg France.
EA 7501, GICC, Université de Tours; Service de Rhumatologie, CHRU de Tours, France.


in English, French

Biosimilars have demonstrated their equivalence with biologic originators, according to rigorous specifications imposed by the regulatory agencies, the FDA and the EMA. Their development is justified by the very high cost of biopharmaceuticals, and strong incentives for their prescription lead us to hope substantial savings, allowing to finance other innovative molecules. Trastuzumab marked history of the treatment of breast cancer. Four biosimilars of trastuzumab are available for routine use and we will detail the key points of their development.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center